Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
Grocery chain settlement brings Colorado's total opioid settlement recovery past $912 million as state continues negotiating injunctive relief terms with remaining defendants.
Agency will now require only one adequate clinical trial supported by confirmatory evidence, a change officials say reflects advances in biomedical science and could accelerate development of addiction treatments.
CDC data shows historic 37% decline in drug deaths since 2023 peak, but medetomidine, cychlorphine, and nitazenes threaten progress.
ONDCP, SAMHSA, and HUD launch two-day summit to develop national toolkit for treating substance use disorders among homeless populations.
Drug 5-10 times more potent than fentanyl detected in Georgia and Missouri, as new study reveals standard naloxone doses may be insufficient for reversing synthetic opioid overdoses.
With PDUFA date set for June 20, 2026, cytisinicline could become the first novel smoking cessation pharmacotherapy approved by FDA in nearly 20 years.
Lykos Therapeutics slashes workforce by 75% after Complete Response Letter reveals FDA concerns about trial design and durability, forcing psychedelic research firms to reconsider regulatory strategy.
Iowa launches competitive grant program directing 75% of opioid settlement funds toward prevention, treatment, and recovery services across the state.
Phase 3 study of 339 adults finds cheap, widely available medication cuts meth use by seven days per month, offering first pharmacological treatment option for stimulant use disorder.